Estrogen and progesterone receptors in breast cancer - current state of knowledge
Journal Title: Współczesna Onkologia - Year 2005, Vol 9, Issue 9
Abstract
The expression of estrogen and progesterone receptors provides strong and useful predictive factors. As the response to hormonal treatment is closely related to the content of estrogen and progesterone receptors in breast cancer, an assessment of the expression of these receptors allows us to predict the response of the cancer cells to hormonal treatment. The expression of estrogen and progesterone receptors is a weak prognostic factor. Statistically significant, positive prognostic effects of estrogen and progesterone receptor expression can only be shown in studies with large numbers of cases. In small or medium scale studies, the prognostic influence of the expression of estrogen and progesterone receptors is weak or absent. For almost four decades, the action of estrogens was attributed to one receptor. However, in 1996, a new estrogen receptor, estrogen receptor beta, was discovered. The first, well known and well characterized receptor, described five decades ago, was defined as estrogen receptor alpha. Estrogen receptor beta is encoded by a different gene to estrogen receptor alpha. The progesterone receptor also has two isoforms: A and B. Both progesterone receptors are encoded by the same gene, but different promoters are used for its transcription. The structure of both proteins is very similar. Nowadays, three methods are used for the assessment of the expression of steroid receptor content in breast cancers: the Ligand Binding Assay (LBA), Enzyme Immuno Assay (EIA) and Immuno Histo/Cytochemical Assay (IHA/ICA). The results of assessments performed with the use of these methods are similar.
Authors and Affiliations
Janusz Piekarski
Keywords
Related Articles
- EP ID EP154551
- DOI -
- Views 55
- Downloads 0
Screening in colorectal cancer (CRC)
Colorectal cancer (CRC) is one of major health problems in Poland. Every year about 11 000 new cases of CRC (EU about 220 000) are diagnosed; the number of deaths approaches 8 000 (EU 112 000). Five-year free disease sur...
Activity of β-galactosidase and α-mannosidase in the serum of patients with colon adenocarcinoma
Exoglycosidases β-galactosidase (GAL) and α-mannosidase (MAN) take part in the synthesis of glycoconjugates in the endoplasmatic reticulum and Golgi apparatus, as well as their degradation in the lysosomes. An increase...
Leczenie zaawansowanych inwazyjnych grasiczaków na podstawie doświadczeń Oddziału Onkologii Wielkopolskiego Centrum Chorób Płuc i Kliniki Torakochirurgii Akademii Medycznej w Poznaniu
Wstęp: Grasiczaki to rzadko występujące nowotwory z nabłonkowej komponenty grasicy. Pierwszoplanowym leczeniem grasiczaków jest leczenie chirurgiczne, w dalszej kolejności radykalna radioterapia. Coraz większą rolę odgry...
Przednia resekcja odbytnicy – wybrane aspekty jakości życia chorych
Rak jelita grubego jest narastającym problemem nie tylko onkologicznym, ale przede wszystkim zdrowotnym współczesnego społeczeństwa w Polsce i na świecie. Badania nad jakością życia w chorobach przewlekłych są cennym źró...
SCC-Ag, CYFRA 21-1 oraz wybrane wskaźniki laboratoryjne w monitorowaniu leczenia chorych na raka szyjki macicy
Cel: Podjęto próbę określenia użyteczności oznaczeń SCC-Ag oraz CYFRA 21-1, a także wyliczanego na podstawie oznaczeń stężenia kwaśnej alfa-1 glikopoteiny i prealbuminy surowiczego wskaźnika nowotworowego (CSI) w monit...